Switch theme
Sign up to access all valuation multiples
SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.
2015
103
LTM Revenue $23.4M
LTM EBITDA -$0.1M
$22.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SynBiotic has a last 12-month revenue (LTM) of $23.4M and a last 12-month EBITDA of -$0.1M.
In the most recent fiscal year, SynBiotic achieved revenue of $4.3M and an EBITDA of -$8.0M.
SynBiotic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SynBiotic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.4M | XXX | $4.3M | XXX | XXX | XXX |
| Gross Profit | $23.4M | XXX | $1.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | -$0.1M | XXX | -$8.0M | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -184% | XXX | XXX | XXX |
| EBIT | -$0.9M | XXX | -$12.4M | XXX | XXX | XXX |
| EBIT Margin | -4% | XXX | -285% | XXX | XXX | XXX |
| Net Profit | -$1.2M | XXX | -$11.9M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -275% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SynBiotic's stock price is EUR 3 (or $4).
SynBiotic has current market cap of EUR 18.7M (or $21.0M), and EV of EUR 19.6M (or $22.0M).
See SynBiotic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.0M | $21.0M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SynBiotic has market cap of $21.0M and EV of $22.0M.
SynBiotic's trades at 5.1x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate SynBiotic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SynBiotic has a P/E ratio of -17.4x.
See valuation multiples for SynBiotic and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.0M | XXX | $21.0M | XXX | XXX | XXX |
| EV (current) | $22.0M | XXX | $22.0M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | -257.5x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -25.3x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.4x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -39.8x | XXX | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynBiotic's last 12 month revenue growth is 48%
SynBiotic's revenue per employee in the last FY averaged $42K, while opex per employee averaged $0.1M for the same period.
SynBiotic's rule of 40 is -44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SynBiotic's rule of X is 120% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SynBiotic and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 48% | XXX | 203% | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -184% | XXX | XXX | XXX |
| EBITDA Growth | -3115% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -44% | XXX | -136% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 120% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $42K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 324% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SynBiotic acquired XXX companies to date.
Last acquisition by SynBiotic was XXXXXXXX, XXXXX XXXXX XXXXXX . SynBiotic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SynBiotic founded? | SynBiotic was founded in 2015. |
| Where is SynBiotic headquartered? | SynBiotic is headquartered in Germany. |
| How many employees does SynBiotic have? | As of today, SynBiotic has 103 employees. |
| Is SynBiotic publicy listed? | Yes, SynBiotic is a public company listed on BER. |
| What is the stock symbol of SynBiotic? | SynBiotic trades under SBX ticker. |
| When did SynBiotic go public? | SynBiotic went public in 2021. |
| Who are competitors of SynBiotic? | Similar companies to SynBiotic include e.g. Mega Lifesciences, Procter & Gamble Health, Abbott India, Sanofi India. |
| What is the current market cap of SynBiotic? | SynBiotic's current market cap is $21.0M |
| What is the current revenue of SynBiotic? | SynBiotic's last 12 months revenue is $23.4M. |
| What is the current revenue growth of SynBiotic? | SynBiotic revenue growth (NTM/LTM) is 48%. |
| What is the current EV/Revenue multiple of SynBiotic? | Current revenue multiple of SynBiotic is 0.9x. |
| Is SynBiotic profitable? | Yes, SynBiotic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SynBiotic? | SynBiotic's last 12 months EBITDA is -$0.1M. |
| What is SynBiotic's EBITDA margin? | SynBiotic's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of SynBiotic? | Current EBITDA multiple of SynBiotic is -257.5x. |
| What is the current FCF of SynBiotic? | SynBiotic's last 12 months FCF is -$0.6M. |
| What is SynBiotic's FCF margin? | SynBiotic's last 12 months FCF margin is -2%. |
| What is the current EV/FCF multiple of SynBiotic? | Current FCF multiple of SynBiotic is -39.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
